Dyne Therapeutics, Inc. DYN
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -20.76%
- 1 year
- -22.96%
5D -1.64 (-9.37%)
- Market cap
- 2.90B
- EPS (ttm)
- -3.62
- Shares out
- 187.39M
- Forward P/E
- -4.30
- YTD return
- -20.76%
- 1-year return
- -22.96%
- 50-day average
- 16.61
- 200-day average
- 19.28
- Enterprise value
- 2.11B
- Price / book
- 3.12
- Volume
- 2.22M
- Avg volume
- 2.92M
- Open
- 15.91
- Previous close
- 16.03
- Day's range
- 15.41 – 16.48
- 52-week range
- 14.00 – 27.31
- Beta
- 1.21
- Analysts
- Strong Buy
- Price target
- 34.33 (+121.5%)
- Earnings date
- Mar 1, 2027
Key statistics
- Free cash flow
- -367.76M
- Total cash
- 1.13B
- Total debt
- 244.28M
- Return on equity
- -74.56%
- Short % of float
- 16.62%
Fundamental scorecard
4 of 25 checks passed on DYN’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 10.00
- Target (mean)
- 34.33
- Target (high)
- 50.00
- Strong buy3
- Buy12
- Hold1
- Sell0
- Strong sell1
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate -1.03.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | -1.00 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.90728 | -1.06 | -0.15 | -16.83% |
| Jul 30, 2026 | Jun 30, 2026 | -0.74878 | -1.08 | -0.33 | -44.23% |
| May 11, 2026 | Mar 31, 2026 | -0.77229 | -0.73 | +0.04 | +5.48% |
| Mar 2, 2026 | Dec 31, 2025 | -0.74 | -0.76 | -0.02 | -2.70% |
| Nov 5, 2025 | Sep 30, 2025 | -0.81 | -0.76 | +0.05 | +6.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Oppenheimer | down | Outperform | Perform |
| Sep 30, 2026 | Chardan Capital | main | Buy | Buy |
| Sep 30, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 29, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Sep 9, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 9, 2026 | JP Morgan | down | Neutral | Underweight |
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dyne-tx.com
News
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics (NASDAQ:DYN) Share Price Breaks Below 50-Day Moving Average on Insider Selling
PepGen Stock Doubles in One Session - Here's Why Dyne Therapeutics Q3 EPS $(1.06) Misses $(0.92) Estimate
Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Why Limbach Holdings Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Oppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15
Your note
Sign in to keep a note on DYN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BESKROVNAYA OXANA | Officer | Sale | Mar 10, 2025 | 195,840 |
| COX JOHN | Chief Executive Officer | Sale | Nov 12, 2026 | 423,994 |
| FRIEDL-NADERER JOHANNA | Officer | Sale | Nov 12, 2026 | 152,666 |
| KERR DOUGLAS | Officer | Sale | Nov 12, 2026 | 167,960 |
| KERSTEN DIRK | Director | Sale | Jul 26, 2026 | 0 |
| LUBNER DAVID CHARLES | Director | Stock Gift | Apr 23, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 18.30% | 34,273,516 | 531.24M | Sep 29, 2026 |
| Blackrock Inc. | 7.73% | 14,471,562 | 224.31M | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 6.43% | 12,042,371 | 186.66M | Sep 29, 2026 |
| FMR, LLC | 5.95% | 11,146,369 | 172.77M | Sep 29, 2026 |
| Wellington Management Group, LLP | 5.65% | 10,579,924 | 163.99M | Sep 29, 2026 |
| State Street Corporation | 4.36% | 8,158,310 | 126.45M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 3.74% | 7,004,602 | 108.57M | Jun 29, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 2.46% | 4,602,629 | 71.34M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.39% | 4,471,727 | 69.31M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.32% | 4,349,704 | 67.42M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.13% | 3,986,208 | 61.79M | Sep 29, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 2.03% | 3,809,721 | 59.05M | Jun 29, 2026 |
